Although there are no clinical trials on RT+anti-TIGIT therapy, combining RadScopal (HDRT: 3 × 12 Gy; LDRT: 2 × 1 Gy), anti-TIGIT therapy and anti-PD-1 therapy significantly affected outcomes by controlling both primary and metastatic 344SQ-P tumors.187 Adding FlT3L to increase CD103+ DC proliferation in the tumor site improved the synergetic effects of RT+anti-TIGIT therapy in MC38 and B16F10 mouse models.188. This evidence concerns the gene PDCD1 and neoplasm.